Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ:NTRB) is a pioneering health and pharmaceutical company headquartered in Oviedo, Florida, with a core focus on transdermal and topical technologies for product development. The company is well-known for its innovative approach to drug delivery, particularly through its proprietary AVERSA™ technology, which aims to prevent the abuse, misuse, diversion, and accidental exposure of transdermal patches containing drugs with abuse potential such as opioids.
Nutriband's flagship product is the AVERSA™ Fentanyl patch, which integrates its abuse-deterrent technology with an FDA-approved transdermal fentanyl patch. This breakthrough product is designed to address the serious issue of transdermal patch abuse and accidental pediatric exposure, which according to recent data, continues to result in major medical outcomes and even death. The AVERSA™ Fentanyl patch has the potential to be the first opioid patch with abuse-deterrent properties and is estimated to reach peak annual US sales of $80M - $200M.
The company's innovative approach includes a portfolio of abuse-deterrent transdermal products targeting drugs such as buprenorphine and methylphenidate, which are prone to the risk of abuse and misuse. Nutriband utilizes its proprietary taste aversion technology, which makes the patches unappealing and difficult to tamper with, thereby reducing the likelihood of recreational abuse or accidental ingestion by children.
In addition to its pharmaceutical advancements, Nutriband Inc. has expanded its portfolio through its wholly-owned subsidiary, Active Intelligence, which focuses on the manufacturing of Kinesiology Tapes and has partnered with major fitness brands like Reebok and Adidas.
Recent developments include the completion of an $8.4 million private placement to fund the commercial development of AVERSA™ Fentanyl and its anticipated NDA filing with the FDA in Q1 2025. This funding will support the pivotal laboratory and clinical studies required for regulatory approval. Nutriband intends to leverage the 505(b)(2) NDA regulatory pathway, which streamlines approval for drugs that have been previously approved, thereby reducing the need for extensive clinical trials.
For more detailed information, visit the company's website at www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its manufacturing subsidiary, Active Intelligence, has successfully received cGMP certification after a thorough audit. This certification is vital for expanding their contract manufacturing services on a national and international scale. CEO Gareth Sheridan highlighted that this achievement will enable the company to enhance its product offerings and explore new market opportunities, which are crucial for the company’s growth strategy.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its CEO Gareth Sheridan and President Serguei Melnik, accompanied by board members and senior management, will ring the NASDAQ Opening Bell on December 3, 2021, at 9:30 a.m. EST. Sheridan expressed gratitude for the teamwork and support that enabled the company’s journey so far. Nutriband focuses on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA™ technology. A live stream of the ceremony will be available online.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has launched the development of its lead product, AVERSA™ Fentanyl, aiming to create the world’s first abuse-deterrent fentanyl transdermal system. This initiative follows the company's uplisting to NASDAQ and new financing. The focus will include developing a commercial strategy, market assessment, and selecting a manufacturer to expedite market entry. CEO Gareth Sheridan emphasized the importance of improving safety while ensuring accessibility for patients. Nutriband specializes in transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report on Bloomberg TV on November 13 at 7 p.m. ET. The program reaches approximately 73 million homes in the U.S. RedChip has 30 years of experience in small-cap investing commentary and interviews with public company executives.
Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA® technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the receipt of $2,062,500 from the exercise of 275,000 warrants at $7.50 each, linked to its earlier public offering on October 1, 2021. This adds to the $6,600,000 garnered from the sale of 1,056,000 shares, bringing the total gross proceeds to approximately $8,662,500 as of October 21, 2021. Nutriband focuses on developing transdermal pharmaceutical products, particularly an abuse deterrent fentanyl patch utilizing its AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has entered an exclusive manufacturing agreement with Diomics for its Diocheck™ technology, aimed at monitoring COVID-19 antibody levels. This transdermal patch provides results within 24 to 36 hours and remains effective for up to 14 days. The device is intended for assessing the effectiveness of COVID-19 vaccines over time, helping identify when boosters may be needed. The partnership showcases Nutriband's capabilities in innovative patch technologies, bolstering its position in the pharmaceutical market.
WallachBeth Capital has successfully completed an underwritten public offering for Nutriband Inc. (NASDAQ: NTRB), raising $6.6 million by issuing 1,056,000 units at $6.25 per unit. Each unit contains one share of common stock and one warrant, with the warrants priced at $7.50 for five years. A 45-day option to purchase additional shares and warrants has been granted to underwriters. The offering commenced trading on October 1, 2021, on the Nasdaq Capital Market.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced an underwritten public offering of 1,056,000 units priced at $6.25 per unit, generating gross proceeds of $6.6 million. Each unit consists of one share of common stock and one warrant. The warrants are exercisable at $7.50 and expire in five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. This uplisting to the Nasdaq Capital Market aims to enhance visibility and support the company's strategic growth initiatives in developing transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that it received a Notice of Allowance from the USPTO for patent application 16/707,547, focusing on its AVERSA® technology. This technology targets the prevention of opioid abuse, particularly for fentanyl patches. The announcement follows the company's initial NASDAQ listing and a $6.6 million underwritten offering on October 1, 2021. The proceeds will primarily fund the clinical development of AVERSA.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
What is the AVERSA™ Fentanyl patch?
What recent achievements has Nutriband Inc. made?
What partnerships does Nutriband Inc. have?
What are the potential market sales for AVERSA™ Fentanyl?
What is the significance of the 505(b)(2) NDA regulatory pathway for Nutriband?
How does Nutriband address accidental pediatric exposure to fentanyl patches?
What other products are in Nutriband’s development pipeline?
Where can I get more information about Nutriband Inc.?
